CN1037835A - The compositions of sustained release - Google Patents
The compositions of sustained release Download PDFInfo
- Publication number
- CN1037835A CN1037835A CN89103575.3A CN89103575A CN1037835A CN 1037835 A CN1037835 A CN 1037835A CN 89103575 A CN89103575 A CN 89103575A CN 1037835 A CN1037835 A CN 1037835A
- Authority
- CN
- China
- Prior art keywords
- matrix
- active substance
- compositions
- surfactant
- basically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 251
- 238000013268 sustained release Methods 0.000 title claims abstract description 11
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 11
- 239000011159 matrix material Substances 0.000 claims abstract description 184
- 239000013543 active substance Substances 0.000 claims abstract description 178
- 238000000034 method Methods 0.000 claims abstract description 127
- 229920000642 polymer Polymers 0.000 claims abstract description 105
- 239000004094 surface-active agent Substances 0.000 claims abstract description 88
- 230000003628 erosive effect Effects 0.000 claims abstract description 50
- 239000002250 absorbent Substances 0.000 claims abstract description 22
- 239000008346 aqueous phase Substances 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 17
- 238000001746 injection moulding Methods 0.000 claims abstract description 16
- 229920001971 elastomer Polymers 0.000 claims abstract description 12
- 239000000945 filler Substances 0.000 claims abstract description 12
- 238000007906 compression Methods 0.000 claims abstract description 8
- 230000006835 compression Effects 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims description 52
- 238000000576 coating method Methods 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 28
- -1 fatty acid esters Chemical class 0.000 claims description 26
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 210000001124 body fluid Anatomy 0.000 claims description 16
- 239000010839 body fluid Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 230000008595 infiltration Effects 0.000 claims description 8
- 238000001764 infiltration Methods 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000003618 dip coating Methods 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000012875 nonionic emulsifier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 4
- 229960004291 sucralfate Drugs 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 244000173166 Pyrus ussuriensis Species 0.000 claims description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000000806 elastomer Substances 0.000 claims description 2
- 239000013536 elastomeric material Substances 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 229950007687 macrogol ester Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002631 room-temperature vulcanizate silicone Polymers 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000004636 vulcanized rubber Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 7
- 238000000465 moulding Methods 0.000 claims 3
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 241000238876 Acari Species 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 235000005206 Hibiscus Nutrition 0.000 claims 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims 1
- 244000048199 Hibiscus mutabilis Species 0.000 claims 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 claims 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 238000013040 rubber vulcanization Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 26
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 19
- 229930182566 Gentamicin Natural products 0.000 description 19
- 239000012530 fluid Substances 0.000 description 17
- 239000010410 layer Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 14
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 14
- 230000010349 pulsation Effects 0.000 description 13
- 229960000278 theophylline Drugs 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 239000012736 aqueous medium Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229960005181 morphine Drugs 0.000 description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical group OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 7
- 235000012756 tartrazine Nutrition 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960005195 morphine hydrochloride Drugs 0.000 description 5
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 101100129922 Caenorhabditis elegans pig-1 gene Proteins 0.000 description 3
- 101100520057 Drosophila melanogaster Pig1 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000446313 Lamella Species 0.000 description 3
- 241000233855 Orchidaceae Species 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ORYOIBJWFDNIPD-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O ORYOIBJWFDNIPD-UHFFFAOYSA-N 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 2
- 229960003203 erythromycin estolate Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011889 obduction Methods 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000576 supplementary effect Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KWEKXPWNFQBJAY-UHFFFAOYSA-N (dimethyl-$l^{3}-silanyl)oxy-dimethylsilicon Chemical compound C[Si](C)O[Si](C)C KWEKXPWNFQBJAY-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FHFZEKYDSVTYLL-UHFFFAOYSA-N Methomidate Chemical compound COC(=O)C1=CN=CN1C(C)C1=CC=CC=C1 FHFZEKYDSVTYLL-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- DSVRVHYFPPQFTI-UHFFFAOYSA-N bis(ethenyl)-methyl-trimethylsilyloxysilane;platinum Chemical compound [Pt].C[Si](C)(C)O[Si](C)(C=C)C=C DSVRVHYFPPQFTI-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- BITPLIXHRASDQB-UHFFFAOYSA-N ethenyl-[ethenyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound C=C[Si](C)(C)O[Si](C)(C)C=C BITPLIXHRASDQB-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RSNQKPMXXVDJFG-UHFFFAOYSA-N tetrasiloxane Chemical compound [SiH3]O[SiH2]O[SiH2]O[SiH3] RSNQKPMXXVDJFG-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Prepare a kind of method for compositions, said composition by with the substantially invariable erosion rate sustained release active substance on its one or more surfaces to aqueous phase, this method comprises at least a water-soluble basically crystalline polymer, consumption is one or more surfactants of 0~50% of crystalline polymer and surfactant weight, at least a active component and random a kind of filler mix, and form a kind of matrix.Compositions can also prepare by room temperture rubber vulcanization (RTV rubber) is mixed a kind of matrix of formation with super-absorbent polymer particles and at least a active substance.Said composition can by extrude, coextrusion, injection moulding or compression forming prepare.
Description
The present invention relates to the compositions of a kind of sustained release active substance to aqueous phase.
As everyone knows, the powder of active substance such as pharmaceutically active is put into the matrix that a kind of insoluble matter constitutes, this active substance can therefrom little by little ooze out, and obtains the lasting release of active substance thus.With semi-permeable coating be coated onto a tablet in the heart, water and lysed active substance can pass through this coating penetration, perhaps foraminous undissolved coating is coated onto tablet in the heart, active substance discharges by this coating, can reach the lasting release of the supercentral active substance that is included in tablet thus.In addition, with active material particle with microencapsulated in one or more layers film, also can obtain the release gradually of active substance, this film can have different types as cause the medium type that active substance oozes out or discharges in intestinal.
These conventional methods that active substance continue to be discharged have certain shortcoming, when the form of dosage is when being present in the body, are the constant densities that are difficult to maintenance active substance in whole process with these methods, as the constant density of blood plasma Chinese medicine active substance.Particularly for the medicine that an of short duration half-life is arranged in vivo, this may be a problem.In addition, water may cause the hydrolysis of the unsettled active substance in water-bearing media by the infiltration of permeability coating.
The objective of the invention is to overcome these shortcomings and a kind of compositions is provided, the said composition strict sustained release of energy active substance wherein, and can prevent that active substance can be owing to hydrolysis is degraded before release time.
Therefore, relate to a kind of compositions in a kind of example of the present invention, control the release of active substance to aqueous phase by one or more surfaces of corroding said composition with substantially invariable speed, said composition comprises:
It is a kind of by the water miscible crystalline polymer or the matrix that mixture constituted of water miscible crystalline polymer basically basically,
A kind of surfactant or surfactant mixtures, they measure with the weight of crystalline polymer and surfactant, consumption with 0~50% be dispersed in crystalline polymer mutually in, this surfactant comprises one or more chemical compounds, this chemical compound have at least a and the corresponding to regional structure of crystalline polymer and at least another kind come down to lipophilic regional structure, and has a fusing point that is lower than crystalline polymer
At least a active substance, it can be evenly dispersed in basically crystalline polymer mutually in and/or on how much, be arranged in the mutually univocal zone of crystalline polymer and/or be dispersed in surfactant and any one filler,
This surfactant and/or active substance reduced in the crystalline polymer matrix and the intergranule of crystalline polymer matrix itself and slit in the affinity of water of regional structure, substantially eliminated the infiltration of water in the interface between the polymer crystallization thus, therefore the dissolution of aqueous medium on one or more surfaces of the compositions by being exposed to medium, and corrode effectively.
For fear of being present in active substance in the matrix because the effect of water, be easy to hydrolysis and the situation of the Degradation of active substance takes place, the combination of matrix and active substance and/or surfactant must be can not be penetrated in the liquid of water to go basically, body fluid for example, promptly this body fluid demonstrates and compositions of the present invention can be incorporated into the intravital part of body (as at gastrointestinal tract, comprise rectum, at vagina or subcutaneous) or be incorporated in the body cavity (as the bladder of urinary system through conduit, gallbladder, the uterus, the central nervous system chamber, infectiousness/pernicious/postoperative cavity etc.).Water has been eliminated basically to the osmosis of this active substance in the intravital inclusions of base, therefore makes compositions become stable, to such an extent as to even said composition is exposed among body fluid or other liquid in the given time, it is active that this active substance still keeps.Because liquid can only act on the surface of this class mold base, so discharge or during firm discharging, it just is exposed in the aforesaid liquid from matrix when the active substance of wherein putting into.Because release is what to carry out gradually from the matrix surface that is exposed to aforesaid liquid; so when compositions is present in the water (as body cavity); basically certain type of impermeable water matrix will be guaranteed the active agent stability in the matrix in all stage; when this active substance discharges, and will guarantee the controlled and rate of release that can reproduce of active substance from matrix.
The speed that active substance discharges from matrix is a predetermined speed, the speed that can control in promptly during certain.Each required especially rate of release depends on especially and will exert one's influence with the amount of active substance that predictive role takes place with its release and to it, and the total dosage that depends on the active substance that matrix comprises.According to guaranteeing that active substance discharges one or more principles of needed amount, select to form the material and the distribution of active substance in matrix of matrix.
The advantage of compositions of the present invention is: the dosage of included active substance can be determined in the matrix, therefore is present in the whole process of water in compositions, can obtain the dosage of the suitable constant or pulsation of active substance at aqueous phase; The characteristic of basal body structure, i.e. its water impermeability, even active substance this be unsettled in aqueous medium, also can prevent because water is penetrated into the degraded that active substance hydrolysis in the matrix or other factors etc. are produced.
Owing to can obtain the sustained release of active substance from compositions of the present invention, so in a specific time, can access the constant release rate of the active substance that accords with the needed dosage of above-mentioned disposal or the pulsation of control discharges, therefore to observe strict dosage instructions about how to take medicine, can be as the usage of the medicament of needs according to administration at interval until administration for several times in a day.In addition, in compositions of the present invention, may comprise the active substance that two or more are different, to be suitable for and by different concentration and/or to be released, so to make the instructions about how to take medicine that patient is easy to observe doctor's advice at interval.
Compare with known other sustained release compositionss, the other advantage of compositions of the present invention is: can be by fairly simple, cheap method is produced, as the extrusion method that describes in detail being produced by following, in addition, the active substance of being convenient to make higher concentration according to said composition of the present invention combines with the size of corresponding said composition, this obviously is a very big advantage, particularly especially true when compositions is used to the release of pharmaceutically active substance, because it is convenient to discharge the amount of needed active substance, and it is unnecessarily big to need not the size of compositions.In addition, because this class material is consistent with the lipophilic regional structure of surfactant, therefore minimal amounts of dissolved or undissolved active substance may be easy to be incorporated in the compositions of the present invention, for example compositions of the present invention can be used for the minimal amounts of dissolved that is difficult to take with additive method or the release of undissolved medicated powder.
This matrix does not comprise water-soluble crystalline polymer or these mixture of polymers, and comprise water-insolube and active substance material together, and at least in part near aqueous phase liquid and in the presence of said liquid expansible hydroaropic substance, its result then is near matrix partial fracture and discharge active substance hydroaropic substance.
Therefore, another kind of example of the present invention relates to and controllably discharges the compositions of certain active substance to aqueous phase, and it comprises:
The matrix of a kind of room temperture rubber vulcanization (RTV rubber), wherein the granule of super-absorbent polymer is distributed substantially equably, and these super-absorbent polymer particles approach basically compositions the surface and
At least a active substance, this active substance are evenly dispersed in basically in the matrix and/or on how much and are arranged in the univocal zone of this matrix,
Wherein, aqueous phase liquid can be penetrated into the surface of matrix with conditional speed, consequently this super-absorbent polymer particles expands, and makes near matrix partial fracture expanded granular, with a specific control method it is discharged according to the distribution of active substance in matrix thus.
In first kind of example of the present invention, promptly comprise water miscible basically crystalline polymer or basically during the mixture of water miscible crystalline polymer when the matrix of compositions, surfactant generally will be dispersed in crystalline polymer mutually in.
This surfactant comprises one or more chemical compounds, they have at least a and the corresponding to regional structure of crystalline polymer and at least another kind be lipophilic regional structure basically." consistent " speech that uses in the context of the invention is meant that surfactant as described below can emulsifying in the polymer of fusing.This surfactant partly plays the effect of repairing medium, surfactant has and makes itself and the crystalline polymer hydrophilic region structure of affinity mutually therein, can fill it into thus in the intercrystalline and slit of crystalline polymer matrix, and this surfactant partly plays the effect of surfactant, because their lipophile regional structures have basically reduced water in the intercrystalline of crystalline texture and the affinity on the median surface, slit, eliminated the infiltration of the water on interface between the polymer scale crystal thus basically therein.
Slit in the above-mentioned crystalline polymer matrix and crystal grain are the products in the crystallization forming process.Matrix shrinks and trends towards forming the slit and form the not intact positive zone of intergranule in crystallization process.In order to keep the effect of the reparation medium that surfactant plays, this surfactant should be movably in the matrix polymer material cured and after having formed crystallization.Therefore, the fusing point of surfactant must be lower than the fusing point of crystalline polymer phase.
In order to make surfactant normally play the effect of repairing medium, be necessary to make in the molten polymer before crystallization surfactant to distribute equably basically for the slit and the crystal grain of matrix.Therefore, surfactant must in this molten polymer, become emulsifying surfactant.
Have been found that hydrophobic basically active substance helps to make surfactant to reach more equably and disperses, reduced the erosion rate of compositions thus.And hydrophilic or water-soluble basically active substance has shown and has had opposite effect, and promptly they trend towards causing surfactant to disperse not too uniformly in matrix.
Substantial portion for the surfactant in determined independent, sizable regional structure, resultant composition has sizable regional structure that comprises crystalline polymer and active substance, can improve the erosion rate of compositions thus.In addition, have found that, if the compositions of preparation does not comprise active substance, the size of the regional structure of the surfactant that it comprised will be greater than having the regional structure size that is essentially the prepared compositions of hydrophobic active material, and this compositions that lacks certain active substance will suffer erosion with quickish speed.
Therefore, the degree of scatter of surfactant in matrix is important to the erosion rate of matrix, disperses to cause the regional structure of many and less more surfactant all the more uniformly, and slower erosion rate.
When with not being hydrophobic active substance when preparing compositions in fact, or when activity substance content in the compositions is low, then need to add one or more fillers, with dispersion that improves surfactant and the erosion rate that reduces matrix.It is believed that the effect that adds filler is the viscosity that improves surfactant, thereby surfactant is disperseed in matrix more equably.The example of the filler that is fit to is, dextrin, Sucralfate, calcium hydroxy apetite, calcium phosphate, soap such as magnesium stearate.The amount that filler can add should make the mixing of filler and active substance reach the about 60% of composition weight, typically can reach about 50%.
This surfactant is generally nonionic emulsifier, this emulsifying agent contains one or more fatty acid esters and/or fatty acid ether, for example have by 12~24 carbon atoms, be typically the fatty acid ester and/or the fatty acid ether of 12~20 carbon atom carbochains, as palmitic acid or stearic certain fat and/or ether.Exemplary surfactants can comprise and contains macrogol ester or ether, polyethylene glycol ester or ether, and poly-hydroxy ester or ether and/or sugar ester or ether are as dehydration Pyrusussuriensis (sugar) alcohol ester or ether.Surfactant will suitably have the hydrophile-lipophile balance value (HLB) of an about 4-16.In addition, preferably a kind of emulsifying agent that goes through to be used to the product (being medicine and/or food) of the mankind or animal picked-up of surfactant.Surfactant is a polyethylene glycol mono stearate preferably, particularly the PEG400 monostearate.The lactate of tartaric acid, citric acid, monoglyceride and diglyceride, and the fatty acid ester of glycerol also can be used for surfactant.
Especially working as active substance is polarity chron basically, surfactant mixtures need be incorporated in the matrix and go, so that improve the dispersion and the reduction erosion rate of original surfactant in matrix.
In some cases, active substance itself can play surfactant, be that it will have at least one with the mutually corresponding to regional structure of crystalline polymer with another is essentially hydrophilic regional structure at least, so active substance self will be basically can be disperseed equably in mutually at crystalline polymer, and eliminates the infiltration of water to matrix basically.In this case, the effect of surfactant, promptly its reparation medium of plaing a part and as surfactant will partly or entirely be finished by active substance itself, only need on a small quantity or not to need surfactant.Therefore, when active substance itself has the characteristic of nonionic emulsifier, can not use surfactant in the compositions, or its consumption only limits to about 0~2% of matrix weight in compositions.In the ordinary course of things, it is preferably PEG400 single-hard ester acid ester of surfactant, reach active substance and have the characteristic of nonionic emulsifier, the PEG400 single-hard ester acid ester can partly or entirely be replaced by another kind of non-ionic surface active agent, with the characteristic of compensation active substance.
When active substance does not have the characteristic of surfactant, the content of surfactant measures by crystalline polymer and surfactant weight and generally is approximately 2~60% in the compositions, for example be approximately 5~50%, typically be approximately 10~40%, more typically be approximately 15~35%, as about 20~30%.But, as mentioned above, when active substance has the characteristic of surfactant, then surfactant can use the consumption less than 2%, in addition, according to the character of surfactant, active substance and crystalline polymer, and the release characteristics of needed compositions, the maximum level of surfactant is approximately 60%, repair that this content is required with sufficient to guarantee and Action of Surfactant.
The matrix of crystalline polymer generally comprises a kind of Polyethylene Glycol, promptly with homopolymer and/or the formed Polyethylene Glycol of copolymer.The better polymerization thing is Polyethylene Glycol or the block copolymer be made up of oxirane and propylene oxide.The molecular weight that is suitable for use in the Polyethylene Glycol in the crystalline polymer matrix is approximately 2000~500, and 000 dalton typically is approximately 5000~100,000 dalton, more typically be about 10,000~50,000 dalton, especially typically be approximately 20,000~35,000 dalton.The molecular weight of Polyethylene Glycol is approximately 35,000 dalton preferably.Typical block copolymer is made up of up to 30% polypropylene oxide base block weight, and its molecular weight is approximately more than 5000 dalton, typically is approximately 5000~30,000 dalton, more typically is approximately 8000~15,000 dalton.
This crystalline polymer matrix must have the fusing point that is higher than the aqueous medium temperature, and wherein, compositions of the present invention will be used in this aqueous medium.Therefore, according to how being used of compositions, the fusing point of the polymer that it uses in matrix is approximately 20~120 ℃, typically is approximately 30~100 ℃, more typically is approximately 40~80 ℃.Particularly when compositions of the present invention was used to the release of people or medicine for animals, the suitable fusing point of this matrix was approximately 40~80 ℃.
According to the present invention, the active substance that the thing that is combined discharges can be people or medicine for animals, vitamin or other supplementarys, disinfectant, deodorizer or in aqueous environments other materials of successive administration.
Compositions of the present invention is particularly suitable for the release of active substance, and this active substance is an active medicinal matter, particularly active medicated powder.Active medicinal matter or the material that is included in the present composition can be selected from multiple treatment kind, particularly are selected from those and can adopt oral, rectum, vagina or material subcutaneous or by body cavity (as the back cavity etc. of bladder, gallbladder, uterus, central nervous system's cavity, infectiousness/pernicious/operation) administration easily.These materials are antimicrobial drugs, analgesic, anti-inflammatory agent, the counterirritation medicine, the improvement medicine condenses, diuretic, sympathomimetic drug, anorexigenic, antacid and other gastrointestinal tract medicines, antiparasitic, antidepressant drug, antihypertensive, anticholinergic, analeptic, antihormone, maincenter and respiratory stimulant, Drug Antagonists, the lipid regulator, uricosureic agent, cardiotonic glycoside, electrolyte, Ergota and derivative thereof, expectorant, hypnotic and sedative, the anti-diabetic medicament, the dopaminergic agent, Bendectin, muscle speeds to delay agent, secondary sympathomimetic drug, anticonvulsant, antihistaminic, beta blocker, clean medicine, anti-arrhythmic, the contrast medium material, radiopharmaceuticals, antiallergic agent, the tranquillizer, vasodilation, antiviral agents, have the medicine of anticancer property with antineoplastic agent or cytostatic agent or other, or their combination.Other active substances that are fit to can be selected from contraceptive and vitamin, and trace and macronutrient.
In addition, compositions also is suitable for the release of polypeptide, for example hormone such as growth hormone, enzyme is fat (fat) enzyme, protease, carbohydrase, amylase, lactoferrin, lactoperoxidase, lysozyme, micropartical for example, or the like and antibody.Said composition also can be used for the release of microorganism, this microorganism can be that live, thin and delicate or dead, antibacterial for example, gastrointestinal tract antibacterial such as streptococcic, for example streptococcus faecalis, Bacillus SPP. such as bacillus subtilis and bacillus licheniformis, breast (acid) Bacillus, aspergillus SPP.bifidogenic factors, or adeno-associated virus (AAV) is as originating in virus, enterovirus, phage such as vaccine and fungus such as bakery yeast, beer yeast and (End) Gammaproteobacteria entirely not.Said composition can also be used to be released in the active substance on the specific support, and this carrier can be liposome, cyclodextrin, micropartical, micelle and fat.
One of purposes that the present composition is well suited for is to discharge antimicrobial drug to vagina, this antimicrobial drug is an antifungal agent, for example imidazoles antifungal agent such as clotrimazole, econazole, Ketoconazole and Miconazole, polyene antifungal antibiotics such as nystatin and antiprotozoal such as metronidazole and α-(chloromethyl ester)-2-methyl-5-nitre imidazoles-1-ethanol.
About 0.1 micron~500 microns of the granular size that is suitable for that active medicated powder by compositions administration of the present invention has typically is about 0.5~300 micron, more typically is about 1 micron~200 microns, especially typically is about 5 microns~100 microns.
This active substance consumption that is fit to is to reach 60% of composition weight approximately, typically reaches 50% approximately.60% activity substance content is considered to maximum level, and this maximum level is still considered enough amounts of crystalline polymer matrix and surfactant in the compositions.On the other hand, the activity substance content in the compositions can be less amount, and this will depend on the character and the intensity of above-mentioned active substance.
As mentioned above, surfactant in the crystalline polymer matrix and/or active substance will reduce in the matrix affinity of the water of regional structure in the intercrystalline and slit, substantially eliminated the infiltration of the water on interface between the polymer scale crystal thus, so aqueous medium has influenced erosion significantly to the dissolution on the compositions surface that is exposed to medium.Therefore, water is limited in the surface layer of matrix basically to the infiltration of compositions, and thus, matrix is with the speed of substantial constant and pH value and being etched independently.The zero level basically that has consequently obtained active substance discharges.The meaning of " zero level " speech is meant that when this active substance was evenly distributed basically, the release of active substance was constant with the time basically in matrix.Be arranged under the situation in the univocal zone of matrix on active substance how much, the pulsation of the active component that the result of the constant erosion rate of matrix will be controlled by strictness discharges.
The geometric shape of compositions is important to zero level or the pulsation release that obtains above-mentioned control.Therefore, compositions of the present invention has a kind of geometry preferably in the scheme at one of the present invention, and this shape can make substantially invariable surface portion be in exposed state in the erosion process of matrix.Thereby, this compositions to be shaped as the garden cylindricality that has a kind of coating bar-shaped, this coating is insoluble to and liquid impermeable in the deenergized period of expection basically, as body fluid, and in its one or both ends one opening is arranged.
As the useful polymer of coating preferably those methods that may form with extrusion molding, solution methods or dispersion and the polymer that process.Best is those polymer that are applicable to food stage or pharmaceutical grade performance.This base polymer has cellulose acetate, polyamide, polyethylene, polyethylene terephthalate, polypropylene, polyurethane, polyvinyl acetate, polrvinyl chloride, silicone rubber, latex, multi-hydroxybutyrate, polyhydroxy valerate, politef, polylactic acid or polyglycolic acid and their copolymer, copolymer such as ethene-vinyl acetate copolymer (EVA), s-B-S copolymer (SBS) and styrene-isoprene-styrene copolymer-(SIS).
Coating can further comprise any in the above-mentioned matrix material form, and the erosion rate of this material is slower than remaining part of matrix basically.Therefore, this coating can comprise the matrix of one or more water miscible basically crystalline polymer and certain surfactant, this coating is a kind of in slower than the matrix material that the contains active substance basically coating of the erosion rate of aqueous phase, a kind of thus constant area that is substantially devoid of the matrix of active substance in the erosion process of compositions be exposed and this coating be etched because of the erosion of the matrix that contains active substance again.This type coating will be designed to make its longitudinal erosion speed consistent with the longitudinal erosion speed of matrix basically, and thus, matrix and coating longitudinally corrode towards the core of compositions with substantially the same speed.Therefore, when matrix was corroded fully by aqueous medium, this coating also will be corroded fully.The compositions that has this coating has an outstanding advantage and is: it can be by the release of active substance fully by biodegradation.This coating for example can be the compositions of the PEG400 monostearate of Polyethylene Glycol and considerable quantity.The content of the surfactant in coating (as the PEG400 monostearate) will be determined by the characteristic (as erosion rate and size) of the matrix of the active substance under each particular case.
In addition, this coating may divide or fragmentation after the erosion of matrix.As long as being contained the matrix of active substance, such coating supports, it will stand intact, but after matrix corrodes, it has just lost the ability that remains intact, therefore, it is division or broken just so that matrix fully corrode and release of active agent after, he just can not for example keep arbitrary effective time in the human or animal body.
Also can make the not bar composition with garden cylindricality of band coating, in this case, when active substance is located substantially on compositions outside, can obtain to approach basically the release of the active substance of zero level.
On the other hand, the shape of said composition can be the hollow hemisphere shape of hollow garden cylindricality." the garden cylindrical rod " that the context of the invention is used or " hollow Cylinder " word are understood that not only to comprise the geometry of garden shape cross section, also comprising is other geometries of garden cylindricality basically, for example, flat a little (horizontal stroke) cross section is as being cross section, avette or ellipse garden shape (horizontal stroke) basically.In addition, also can use other geometries, these smaller geometries that only can provide have reduced the surface area of compositions, obtained being evenly distributed on basically the release near zero level of the active substance in the compositions thus, for example had a kind of flat and be the flaky or flat compositions in the cross section of rectangle or ellipse garden shape basically.
The those skilled in the art in present technique field are appreciated that the use for the ease of above-mentioned composition, and the specific shape of making of the present composition can comprise some little improvement.For example, the injury or the discomfort that may cause when introducing said composition in the body, the garden is done in the end that can discharge the garden post clavate compositions of medicated powder.In addition, the hollow interior of the compositions of hollow Cylinder shape can optionally be filled with being easy to dissolved substances, for example use low-molecular-weight Polyethylene Glycol (being about 1500~6000 as molecular weight).
As mentioned above, active substance can be evenly dispersed in the crystalline polymer matrix basically, obtain the situation of the zero level release of active substance basically.On the other hand, comprise that crossbedded compositions of the present invention can obtain the pulsation release of active substance.Therefore, by having above-mentioned garden post clavate and comprising the release that the compositions of some basically staggered transverse layers can obtain pulsing, basic staggered transverse layers comprises one deck crystalline polymer matrix and surfactant and is dispersed in random active component in this matrix and one deck optionally is dispersed in active component in crystalline polymer and the surfactant basically.Equally, the compositions of hollow Cylinder shape can comprise: staggered which floor, should be staggered which floor comprise one deck crystalline polymer matrix and surfactant and comprise that random active component and one deck of being dispersed in basically in this matrix comprise the active component that optionally is dispersed in basically in crystalline polymer and the surfactant.In comprising staggered which floor compositions, these staggered layers can comprise two or more different active substances respectively.
Also can be used in combination these two kinds of releasing patterns (being zero level and pulsation delivery mode), carry out with alternating so that the even release of active substance (as with quite low dosage) is discharged with pulsed identical or another kind of active substance (as with higher dosage) ground.
In another example of the present invention; as mentioned above; can obtain the release that certain active substance enters aqueous phase by a kind of compositions through control; said composition comprises: a kind of room temperature-vulcanized rubber (RTV rubber) matrix; wherein, super-absorbent polymer particles is homodisperse basically, and these super-absorbent polymer particles also are present in the near surface of said composition basically; so that aqueous phase liquid can penetrate in the matrix with limited speed
This just causes this super-absorbent polymer particles to expand and matrix is broken near dilated granule partly, and active substance is discharged.According to embodiments of the invention, water is confined to surface layer basically to the infiltration of compositions, and thus, according to the distribution of this active substance in matrix, active substance is to discharge with specific control mode.
Used RTV rubber typically comprises the RTV silicone elastomer based on one or both components of polydimethylsiloxane.The matrix of RTV rubber contains a kind of catalyst and random a kind of cross-linking agent in addition.The catalyst that is fit to is stannous octoate or is approximately platinum-divinyl tetramethyl disiloxane complex (containing about 3~3.5% platinum) of 0.01~0.1%.The cross-linking agent that is fit to be 0~40% 1,3-divinyl tetramethyl disiloxane, 1,1,3,3-tetramethyl disiloxane or 1,3,5,7-tetramethyl-ring tetrasiloxane.
Super-absorbent polymer particles is more such granules, be that they can be in a kind of semi-solid state by absorbing water or other liquid, and can be absorbed as about 10 times water of himself weight at least, typical about 100 times water that can be absorbed as himself weight at least, special about 200 times water that can be absorbed as himself weight at least.These super-absorbent polymer particles can also absorb body fluids and are in semi-solid state; and can be absorbed as about 5 times body fluid of himself weight at least; typically can be absorbed as about 20 times body fluid of himself weight at least, special about 40 times body fluid that can be absorbed as himself weight at least.The typical super-absorbent polymer that is applicable to example of the present invention is acrylic acid, modified acroleic acid, carboxymethyl cellulose, modified carboxy methyl cellulose and crosslinked polyvinyl pyrrolidone.
The degree of partial fracture will be determined by the rate of release of desirable active substance especially, but under any circumstance, this is enough to make other super-absorbent polymer particles can enter into above-mentioned body fluid, guaranteed thus matrix with basically uniformly speed little by little break from interior surface.Swelliong power and its arrangement mode in matrix according to selected specific super-absorbent polymer, the amount of the super-absorbent polymer that can change in the matrix to be contained, be that benchmark measures its amount that is fit to and is approximately 5~75% with the weight of matrix, typically be approximately 10~50%, more typically be approximately 20~40%.
Included active substance can be above-described arbitrary substance in example of the present invention, promptly be used for people or beastly medicine, vitamin or other supplementary, disinfectant, deodorizer or aqueous environments can successive administration other materials, and the type of listing above and the special pharmaceutically active powder of particle size.The amount of active substance is measured by the weight of compositions and is reached 60% approximately, typically reaches 50% approximately, but it also can be to be present in the compositions with much smaller amount.
Compositions according to example of the present invention also must have a kind of geometry, this geometry can make a kind of substantial constant surface area be in exposed state in the erosion process of matrix, thus, can obtain the zero level release or the pulsation release of needed active substance according to the distribution of active substance in compositions.This particular geometric shapes can be above-mentioned any.
Active substance in example of the present invention can be evenly distributed in the matrix basically, and the zero level that will obtain active substance therein basically discharges.Compositions in this example can also comprise staggered layer, and the pulsation that can obtain active substance therein discharges.Therefore, can obtain having top said garden post clavate and comprise that a kind of pulsation of staggered basically transverse layers discharges according to the compositions in the example of the present invention, should staggered transverse layers be to constitute like this: promptly one deck contains matrix and optionally contains the active component that is evenly dispersed in basically in this matrix, reach one deck and contain active component, this composition optionally is evenly distributed in the matrix material basically.Equally, a kind of compositions of hollow Cylinder shape also comprises staggered longitudinal layer, this layer comprises that one deck contains matrix and optionally contains active component and one deck active component that is evenly distributed in basically in the matrix, and this active component is optionally to be evenly distributed in the matrix material basically.
As mentioned above, staggered layer can comprise two or more different active substances respectively.These two kinds of releasing patterns (zero level and pulsation) equally also can be combined in the compositions of example of the present invention, so that make the even release (as with quite low dosage) of active substance and the carrying out that discharges the ground that alternates pulsedly of of the same race or another kind of active substance (as with higher dosage).
In addition, can be used to prepare the multicomponent pharmaceutical formulation according to the compositions of any one example of the present invention, as form with capsule or tablet.Multiple component drugs composition formula is the prescription that contains multiple independent composition, and these independent compositions are promptly obtained along with the decomposition of prescription in the human or animal's of the above-mentioned prescription of picked-up (being typically capsule or tablet) stomach by this way.So in this case, will be constituted by compositions of the present invention to the small part separate constituent in the above-mentioned multicomponent pharmaceutical formulation, the size of this separate constituent can be introduced into this prescription with them and be as the criterion.
Compositions of the present invention can be made with diverse ways, and these methods are the known methods of medical industry itself, or for example according to employed material in required example and the above-mentioned composition, is employed method in the material preparation on basis at polymer.As mentioned above, one of advantage of the present composition is that it can adopt simple and cheap relatively method to be made.
The compositions of band coating can be by the method for for example extruding, and the method for injection moulding or compression forming makes; And the compositions of coating can be by for example coating and matrix and active substance the coextrusion method, extrude and dip coating injection moulding and dip coating and make, or by extruding or injection moulding and make by spraying or immersion solvent coating.
For preparation contains the compositions of the matrix of crystalline polymer, generally this polymer and surfactant are mixed, are being enough to make under the temperature of polymer melted heating and are stirring, to obtain a kind of mixture uniformly basically.Be included at active substance under the situation of matrix, active substance can be added in the polymer and surfactant mixtures that has melted, or joins before heating in this mixture.The mixture that has melted subsequently is extruded or injection moulding with following method.When preparation was used for the compositions of active substance pulsation release, active substance can be included in the matrix material easily, and the mixture of active substance and matrix material is extruded or is injected into lamella, and this lamella replaces mutually with the lamella that does not contain the matrix of active substance.
The compositions that has the RTV rubber matrix for preparation, the component of matrix, it is the RTV elastomeric material, super-absorbent polymer, with catalyst accelerator and/or cross-linking agent, generally be at room temperature under agitation to mix, this mixture is promptly extruded with following method or injecting method carries out subsequently.According to the characteristic of desired compositions, active substance can join in the mixture before for example extruding or injecting, and perhaps extruded individually or injected.
For example, be the compositions of production garden post rod shape, the matrix material that contains active substance can be injected into a preformed pipe.On the other hand, the compositions of garden post clavate can be made by injecting staggered layer, and this staggered layer comprises matrix material and active substance at least respectively, and they are present in the above-mentioned pipe.Garden post clavate compositions also can make by the method for for example extruding matrix material (active substance disperses wherein), dip coating subsequently, or adopt a) matrix material and the coextrusion and the b that disperse active substance wherein) co-extrusion of coating comes out to make.
Garden post clavate compositions also can make by injection moulding method, comprises coating and the bi-component or the multicomponent injection moulding that contain the matrix of active substance.Injection moulding is particularly suitable for having a kind of compositions of erodable coating or divides or broken coating because of the erosion of matrix, but the method also is applicable to other compositionss, be typically, the first step is for example to examine ferrum nuclear around certain to have made the Cylinder of coating effect, in second step or rapid, inject matrix material after the ferrum nuclear and make matrix by removing with alternative multistep.The advantage of this method is simple, is very suitable for big production.
The compositions of hollow Cylinder shape for example can by extrude, compression forming or injection moulding makes.Compositions with hollow hemisphere shape can make by compression forming or injection moulding.
The special advantage that comprises coextrusion (being used to have garden post clavate preparation of compositions) and extrude the production method of (being used to have hollow Cylinder preparation of compositions) is that they are promptly cheap simply again concerning the big production of compositions of the present invention.Be cut into the suitable less sheet of size by rod or the pipe extruded or the coextrusion method is made, compositions is repaired again, for example the end type of garden post rod or hollow Cylinder can be done the garden.
The matrix material of compositions that with crystalline polymer is basic employed fusing is more faster than the curing based on the matrix of the compositions of RTV rubber.Therefore, included extrusion method usually is more suitable in the manufacturing of the compositions that contains the crystalline polymer matrix, and the compositions that contains the RTV rubber matrix is more suitable in being produced by for example material being injected into the preforming pipe.
Active substance consumption, size and the particular form of the present composition will change according to the purposes of the compositions of the character of above-mentioned active substance and expection certainly.When compositions of the present invention is when being used for compositions that active medicated powder discharges, will depend on patient's year order and health to the special dosage of human or animal's administration, and some factors like this such as the specific condition that will treat.
Hereinafter with reference to accompanying drawing the present invention is described more completely.
Fig. 1 represents a kind of sectional view of garden post clavate compositions of band coating, and said composition is used for the constant release of active substance.Compositions comprises the active substance that is evenly distributed in basically in the matrix 2, and is had the coating 1 of opening to coat by an end.This coating 1 is insoluble in the dispose procedure of expection and liquid impermeable body fluid for example.Therefore, matrix 2 is because of the effect of the aqueous medium of employed compositions, slowly corrode from an end of opening, so that the surface area and the time that make matrix 2 be exposed to water keep constant, active substance can discharge with the speed of constant and the strict control of quilt thus.
The compositions of representing among Fig. 2 is except both ends open, and is identical with the compositions of Fig. 1, and matrix 2 corrodes to core from two openings thus.
Fig. 3 represents the sectional view of the garden post clavate compositions of band coating, and the pulsation that said composition is used for certain active substance discharges.Said composition comprises the horizontal cross-bedding of matrix 2 and certain active substance 3, and is coated by the coating 1 of an end opening.Coating 1 is insoluble to and liquid impermeable such as body fluid in the dispose procedure of expection basically.From then on, this base layer 2 is by the effect of the aqueous medium of employed compositions, slowly corrode from an end of opening, thereby, along with each layer of matrix 2 sequentially is etched, discharge active substance 3 from controlled pulsation.This compositions also can adopt both ends open to prepare.
Fig. 4 represents to be used to discharge the sectional view of the compositions of two kinds of active substances.Steel toe Cuo a kind of scorpion of containing high concentration active substance 3 fastens with a bolt or latch among the handkerchief joke , and wherein another kind of active substance is distributing equably with low concentration again, and said composition coated 1 applies, and coating 1 is water insoluble and liquid impermeable such as body fluid in the dispose procedure of expection.Active substance in matrix 2 is with uniform speed and discharging basically, and the active substance that is included in the layer 3 discharges with pulse mode.
Fig. 5 represents a kind of hollow Cylinder shape compositions, and active substance is evenly distributed in the matrix basically in this compositions.Matrix is etched from the inside and outside of hollow Cylinder, and the surface area that therefore is exposed to aqueous phase liquid is constant with the time, and the zero level that obtains active substance thus discharges.
Fig. 6 represents a kind of hollow hemisphere bodily form compositions, and active substance is evenly distributed in the matrix basically.Matrix is etched from the inside and outside of hollow hemisphere, and therefore, the surface area that is exposed to aqueous phase liquid is constant with the time, thereby the zero level that obtains active substance discharges.
Fig. 7 represents a kind of shape compositions, and this active substance is evenly distributed in the matrix basically.This matrix mainly is to be etched from two big planes, and the surface area and the time that therefore are exposed to aqueous phase liquid are constant, and the zero level that obtains active substance thus discharges.
Fig. 8 represents the sectional view of the garden post clavate compositions of coating 2, and the erosion rate of this coating 2 is lower than the matrix 1 that contains active substance basically.After after a while, matrix 1 corrodes to 4 from each end, corrodes slower coating 2 simultaneously comparatively speaking and corrodes to 3 in liquid.
The present invention is further disclosed in following non-limiting example.
Embodiment 1
Blue Polyethylene Glycol (PEG) 20,000 matrix materials with fusing of patent fully mix.Final matrix contains 25% patent orchid, 75%PEG20,000.Matrix is in 4 millimeters the preforming silicone tube to an internal diameter with a filling apparatus squeeze note while hot the time, makes its cooling subsequently.Then pipe is cut into the sheet of 2 centimeter length, the prescribe medicine form any end leave opening, active substance discharges by opening.Record pipe in during 3 days at synthetic urine (1.94% carbamide, 0.8%MgSO
4, 0.11CaCl
2, 97.1% water) in erosion rate be 4 millimeters/24 hours.
Embodiment 2
Adopt and embodiment 1 described identical method, but the matrix material that uses comprises 90%PEG20,000 and the 10%HLB value be 11.5 PEG400 monostearate, the tubulose that makes is cut into slices and is contained 75% matrix material, 25% patent orchid.Recording the erosion rate of cutting into slices in the synthetic urine in 8 day time is steady state value 1.3 millimeters/24 hours.
Amplify 50~125 times at microscopically and can see and contain PEG20,000 continuous crystallisation phase, the PEG400 monostearate is dispersed in wherein, and the PEG400 monostearate has been caught liposoluble blue color, and is therefore easily in sight.Can see that the PEG400 monostearate is distributed in the whole polymer crystals basically equably, filled simultaneously and " reparation " slit and the interface between the crystalline solid.
With 10.8 gram PEG35,000 and 3.6 gram PEG400 monostearates mix, and heat until fusing under 60~80 ℃ of temperature simultaneously.9.6 gram micro-crystallization theophylline mixes up to obtaining uniform the distribution mutually with the matrix material of fusing.The matrix of this fusing is got in the preformed polyfluortetraethylene pipe (internal diameter is 6 millimeters) and is cooled.Refrigerative matrix is released from pipe by a piston, and the rod of gained is coated with the polyurethane in 20% acetone (Esfane 5712F30) solution.The rod that is coated with is cut into the sheet of 20 millimeters long subsequently.Dosage form is invaded 100 milliliters of (34 grams per liter) simulated intestinal fluid (Revolyt; Component: 22 millimoles/rise bicarbonate, 15 millimoles/rise potassium, 60 millimoles/rise chloride, 3 millimoles/rise magnesium, 67 millimoles/rise sodium and 3 millimoles/rise sulfate) in, constant vibration 28 hours on the rail mounted vibrator under 37 ℃ of temperature is to measure the theophylline amount that is discharged from the dosage form of gained.Got one time sample in per 2 hours,, measure with Perkin Elmer HPLC device by high efficiency liquid chromatography (HPLC) method.
Record the burst size of following theophylline under these conditions:
Release time (hour) burst size (micromolar/liter)
0-2 1380
2-4 1220
4-6 940
6-22 6520(≈ 815/2 hour)
22-24 1055
24-26 850
26-28 810
Under the same conditions, the erosion rate at the matrix of any end of dosage form is 0.44 millimeter/hour.
With 25%PEG35,000,12.5%PEG10,000 and the 12.5%PEG400 monostearate mix, heat under 60~80 ℃ of temperature simultaneously, 49% gentamycin sulfate (powdery) and 1% tartrazines join in the matrix material of fusing, up to the even release that obtains them.The matrix of fusing is squeezed in the preformed polyfluortetraethylene pipe (5 millimeters of internal diameters) and is cooled, and cooled pipe is cut into the sheet of 20 millimeters long.
Except using Beckman DU-R spectrophotometer 430nm measures burst size, measure the gentamycin sulfate that from resulting dosage form, discharges by embodiment 3 described methods.
The gentamycin sulfate burst size that records in during 10 hours is 10~15 milligrams/hour, and the erosion rate of matrix is 1 millimeter/hour.
Embodiment 5
With 36%PEG35,000 and the 24%PEG400 monostearate admixed together, under 60~80 ℃ of temperature, heat simultaneously also.The blue V of 39% gentamycin sulfate (powdery) and 1% patent joins in the matrix material of fusing, distributes equably up to obtaining them.The matrix of fusing is expressed in the preformed polyfluortetraethylene pipe (5 millimeters of internal diameters) and is cooled, and cooled pipe is cut into the sheet of 20 millimeters long.
During 8 hours 638nm measure burst size be the 10-14 milligram/hour, press embodiment 4 described methods mensuration basically, the gentamycin sulfate that from resulting dosage form, discharges.
Embodiment 6
Remove and use PEG35,000 and the PEG400 monostearate as matrix material with use polygynax as outside the active substance, adopt and embodiment 5 described same procedure, prepared tubular piece contains 33.3%PEG35, and 000,33.3%PEG400 monostearate, 32.3% polygynax and 1% tartrazines.
The polygynax that from the dosage form of gained, discharges that records by embodiment 4 described methods be the 8-10 milligram/hour, the erosion rate of the matrix of any end is 2 millimeters/6 hours.
Embodiment 7
The block copolymer (the Synperonic F-88 of ICI) of 8 gram oxirane and propylene oxide and 2 gram PEG400 monostearates mix, under 60~80 ℃ of temperature, heat simultaneously until fusing, 2 blue V of gram patents and the matrix material that has melted mix, this mixture is expressed in the preformed polyfluortetraethylene pipe (4 millimeters of diameters), and is cooled.Cooled pipe is cut into the sheet of 20 millimeters long, and the two ends of sheet are the mouths of opening.Recording the erosion rate of sheet in synthetic urine in during 8 days is steady state value 1.2 millimeters/24 hours.
Embodiment 8
With 0.38 gram D6210(1,3-divinyl tetramethyl silica alkane obtains from PetrarCh) and 4g methyl hydrogen-tetramethylsilane siloxane copolymers (PS123 that obtains from PetrarCh) at room temperature mix.Add the polyacrylic acid of 3 a gram Salsorb 84(modification in mixture, granular size is 90~850 microns, and capacity (in 0.9% NaCl) is 45 gram/grams; Obtain from Allied Golloids Ltd), add 4.72 clarithromycin estolate subsequently again, 0.4 gram catalyst solution (polydimethylsiloxane of 0.03% platinum in 10% cyclic vinyl methylsiloxane and 90% vinyl-dimethyl cardinal extremity base) and 1% patent is blue and fully mixing.Matrix material is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of internal diameters), and at room temperature hardens 4 hours.Pipe is cut into the sheet of 20 millimeters long subsequently.
Except dosage form being immersed in 100 milliliters of simulated gastric fluid (pepsin HCl, PH3) outside in (wherein added the front in the simulated gastric fluid described the simulated intestinal fluid as buffer agent), the erythromycin estolate that discharges from the dosage form of gained press embodiment 3 described methods mensuration basically.
Use the patent orchid as indicator, the 9-10 milligram of the erythromycin estolate that records/hour be released in and drop to about 7 milligrams/hour within 24 hours.Under identical condition, the erosion rate of matrix is 16.5 millimeters/24 hours.
Embodiment 9
With 0.19 gram 1,3-divinylsiloxanes (D 6210 of Petrarch) is at room temperature mixed with 2 gram methyl hydrogen-dimethylsiloxane copolymers (PS123 of Petrarch).In this mixture, add 5 gram carboxymethyl celluloses (A250 of Aqualon), add 5 gram gentamycin sulfate and 0.4 gram catalyst solution (polydimethylsiloxane of 0.03% platinum in 10% cyclic vinyl methylsiloxane and 90% vinyl-dimethyl cardinal extremity base) subsequently.Matrix is expressed in the preformed polyfluortetraethylene pipe (internal diameter is 4 millimeters), and at room temperature sclerosis reaches 2 hours, and this hardened pipe is cut into the sheet of 20 millimeters long then.
The burst size of measuring by the method for embodiment 8 of gentamycin sulfate in simulated gastric fluid is 1.3 milligrams/hour.The erosion rate of matrix is 6 millimeters/24 hours.
Embodiment 10
Comparison example with different components
A) PEG10 by having melted, 000 be expressed into the compositions that contains pure PEG in the preformed polyfluortetraethylene pipe (4 millimeters of diameters) with preparation.After the cooling matrix is released from pipe by a piston, the gained club is coated with the poly-amino solution (Estane5712F30) in acetone with 20%.This coated rod is cut into the sheet of 10 millimeters long subsequently.In simulated intestinal fluid (embodiment 3), the erosion rate of PEG is 4 millimeters/hour.
B) be PEG35 except PEG, beyond 000, compositions and erosion rate by above-mentioned a) the method preparation and measure, erosion rate is 18 millimeters/hour.
C) 95%PEG35,000 and the mixture of 5%PEG400 monostearate be melted the rod that applies by above-mentioned method preparation in a), and to use diameter be 6 millimeters preformed polyfluortetraethylene pipe.The erosion rate that records in simulated intestinal fluid is 1.45 millimeters/hour.
D) 75%PEG35,000 and the mixture of 25%PEG400 monostearate be melted.40% the dextrin that accounts for composition total weight is added in the compositions as filler.Resulting mixture is expressed in the preformed polyfluortetraethylene pipe (10 millimeters of diameters), and presses the rod that method preparation a) applies, and the value of the determination of erosion rate in simulated intestinal fluid is 0.34 millimeter/hour.
E) 75%PEG35,000 and the mixture of 25%PEG400 monostearate be melted, in the mixture that has melted, add as the dextrin of filler with as the mixture of the morphine hydrochloride of active substance,
The amount of dextrin and morphine hydrochloride is 40% of a gross weight.Containing 3.55% the muriatic compositions of morphine is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters).This rod applies and is cut into the sheet of 10 millimeters long according to the method a).The release of morphine hydrochloride in simulated intestinal fluid is measured with high efficiency liquid chromatography (HLPC), in 10 hours is 1 milligram/hour, and erosion rate is 0.43 millimeter/hour.
F) be 9.54% except the content of morphine hydrochloride, prepare compositions by above-mentioned method in a), morphine hydrochloride being released in 10 hours in simulated intestinal fluid that records with the HPLC method is 3 milligrams/hour, and erosion rate is 0.48 millimeter/hour.
G) 75%PEG35,000 and the mixture of 25%PEG400 monostearate be melted, and mix mutually with 3.55% tartrazines.Mixture is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters), applies and be cut into the sheet of 12 millimeters long according to method a).Record in 4 hours, sheet is 1.5 millimeters/hour of steady state values from the erosion rate of every end in simulated intestinal fluid.
H) 10.5 gram PEG35,000 and 3.5 gram PEG400 monostearates are melted and mix.Add 6 gram methotrexate, obtain one and contain 52.2% PEG35, the mixture of 000,17.5% PEG400 monostearate and 30% methotrexate (MTX).It is the rod that applies by the method preparation in a) in 4 millimeters the polyfluortetraethylene pipe that the mixture of this fusing is expressed into diameter.Use the HPLC method, record MTX in during 10 hours and be released to 1.5 milligrams/hour in synthetic urine (embodiment 1), erosion rate is 0.5 millimeter/hour.
I) 5.4 gram PEG35,000 and 1.8 gram PEG400 monostearates are melted and mix with 4.8 gram dextrin/tartrazines (99: 1).It is in 6 millimeters the polyfluortetraethylene pipe that mixture is expressed into diameter, and the method in pressing a) applies, and in 12 hours, when wavelength was 430nm, the erosion that records in simulated intestinal fluid was 0.34 millimeter/hour with spectrophotometer.
J) 1 gram PEG35,000,0.5 gram PEG400 monostearate and 1 gram be single-and the diacetyl tartrate of diglyceride (, Dat-S) be melted in together from Denmark Grindsted product.Add 2.5 gram sucralfate subsequently, mixture is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters).The erosion rate in simulated intestinal fluid that records was 1 millimeter in 8 hours.
K) preparation and j) identical compositions, but do not contain diacetyl tartrate.4 gram PEG35,000 and 2 gram PEG400 monostearates are melted, and add 4 gram Sucralfate in the mixture that has melted.Mixture is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters), and the method in pressing a) applies, and the erosion in simulated intestinal fluid is greater than 2 millimeters in 8 hours.
L) 5 gram PEG35,000 is melted and is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters).One end of pipe be immersed in the fusing that contains 10% tartrazines PEG1500 in.Mixture is taken out from pipe and apply EstaneF30, the end that is impregnated in PEG1500 and the tartrazines mixture is also coated.Compositions is cut into the sheet of 7.5 millimeters long subsequently.Corrode after 4 hours in simulated intestinal fluid, obtain a yellow liquid, it is 1.9 millimeters/hour that this liquid demonstrates its erosion rate.
M) 2.25 gram PEG35,000 and 0.75 gram PEG400 monostearate is melted, and adds 2 gram dextrin (40% dextrin), and mixture is expressed in the preformed polyfluortetraethylene pipe (6 millimeters of diameters).By above-mentioned l) program, make the coated rod that has 3.5 millimeters long of PEG1500+ tartrazines in the end that applies, in simulated intestinal fluid, corrode subsequently.Can see yellow liquid after 8 hours, this yellow liquid demonstrates erosion rate and is about 0.23 millimeter/hour.
Embodiment 11
Have 12 millimeters long except rod is cut into, prepare compositions by embodiment 3 described methods.Resulting rod contains 195 milligrams of PEG35,000,65 milligram of PEG400 monostearate and 170 milligrams of micro-crystallization theophylline.The erosion rate in teat glass that records by embodiment 3 described methods is 1 millimeter/hour, is equivalent to per hour discharge about 15 milligrams of theophylline.The accurate theophylline burst size of being measured by the HPLC method is as follows:
Release time (hour) burst size (micromolar/liter)
0-2 2575
2-4 1740
4-6 1645
6-8 1740
In six patients, measured the release of theophylline from compositions in vivo, 3 male surnames wherein, 3 women surnames, a year order is 18~42 years old (average year makes 30 years old), 63~85 kilograms of body weight (average 66 kilograms), all patients diagnose suffers from the bronchial asthma disease.
Early before the meal (promptly in fasting state) allow patient take dosage for the first time, this dosage is the compositions (340 milligrams of theophylline) and 100 milliliters of liquid of two units.Dosage is after at least 3 days for the second time, give patient at 10 minutes angular vein injection theophylline (Theo-Dur20 mg/ml) in the morning, dosage is 5 milligrams/kilogram of standard body weight), to measure the half-life of theophylline at the intravital serum of single patient.After oral dose, 0,1,2,3,4,6,8,10,12,14,16 and 24 hours venous blood samples samples.At 0,15 minute, 30 minutes, 60 minutes, 90 minutes and 2,3,5,7,9, reach 11 hours and extract the serum blood sample behind the intravenous injection dosage.The serum of blood sample part is freezing under-20 ℃ of temperature immediately, and keeps in this freezing state analyzes after 2 weeks.With the theophylline amount in the HPLC methods analyst serum, degree of accuracy is ± 5%.The serum half-life of the single patient's who records serum content and the theophylline that calculates is shown in following table:
Theophylline amount in patients serum's half serum (micromolar/liter)
Retain the phase
Numbering (hour) 123468 10 12 14 16 24
1 6 21 21 - 22 21 20 17 16 14 11 9
2 9 7 16 24 30 36 32 30 32 30 25 19
3 8 25 38 39 39 39 44 51 50 45 41 30
4 9 11 19 22 26 39 33 29 26 21 19 15
5 7 9 14 19 20 25 21 19 22 16 14 8
6 8 9 21 19 18 20 21 21 22 26 25 18
Embodiment 12
E by embodiment 10) the described detection release of morphine from compositions is in vivo undertaken by two patients, and two patients are healthy male surnames, and year makes 40 years old, and body weight is 85 kilograms (patient 1) and 65 kilograms (patient 2).Early two hours after the meal, the compositions that contains 10 milligrams of morphines that doses a patient with was in the same place with 100 milliliters liquid.By each second hour venous blood samples sample, determine the concentration of morphine in the serum, serum keeps cold state, up to second day serum is isolated and freezing under-20 ℃ of temperature.Morphine concentration three week back in the serum is analyzed with the RIAS method, and this method is with ± 5% the degree of accuracy and the free and conjugated morphine of sensitivity mensuration of the whole morphines of 2ng/milliliter serum.Morphine concentration is listed in the table below in the serum that obtains:
Morphine in the serum (ng/ml)
Hour: 12468 10 12 14 21
Patient 1 18 32 44 46 42 51 76 60 34
Patient 2 35 76 64 44 31 21 27--
Embodiment 13
With 18%PEG20,000,27%PEG35,000 and the 15%PEG400 monostearate mix, and under 65~75 ℃ of temperature, heat, in the matrix material that has melted, add 40% gentamycin sulfate and mix, up to being evenly distributed.The mixture that has melted is expressed in the preformed polyfluortetraethylene pipe (3 millimeters of diameters), and is cooled.Resulting rod is released from pipe by a piston subsequently, and be cut into the piece of 15 or 30 millimeters long, Estane 30 solution impregnation with 20% apply, wherein an end does not apply, press embodiment 3 described methods, in teat glass, record the release of gentamycin, use biological agar hole osmosis chemical examination gentamycin, obtain following result by resultant composition:
Release time (hour) release of gentamycin (micromolar/liter)
0-2 1380
2-4 1220
4-6 940
6-22 6520(930/2 hour)
22-24 1065
24-26 850
26-28 810
The determination of erosion rate of compositions opening one end is 1 millimeter/24 hours, is equivalent to 5 milligrams of gentamycin/24 hour.
Aforesaid compositions is adhered to the top place of the conduit (Ruch, 2F, 5 milliliters, size 12) of urinary system balloon-like.The top tip part diameter is identical with conduit, and the length of compositions is 30 millimeters.
By animal detection release in vivo, use a SPR Danish Landrace X Yorkshire LYY female pigs, body weight is 22 kilograms.This pig is supported at the wire mesh cage that has the stainless steel disc that is used for collecting urine.The bladder that is introduced in pig at conduit uses the Sedaperone(subcutaneous simultaneously) and the Hypnodil(intraperitoneal) make its anesthesia to its injection.Went back injecting atropine (subcutaneous) at that time in case fluid stopping is prolonged.Collected the urine sample of 20 milliliters of equal portions in per 24 hours from tray, gentamicin concentration is measured by using biological agar hole osmosis in the urine, and this method sensitivity is 0.2 microgram gentamycin/milligram urine.The gentamicin concentration that draws is as follows:
Microgram gentamycin/milligram urine
0-24 hour: 1.75
24-48 hour: 1.40
48-72 hour: 1.55
Find that in the 4th day obduction there is hyporrhea the bladder outside, the mucosa and the urethra that observe bladder are normal.
Embodiment 14
Use identical compositions (embodiment 13) as stated above, carry out zooscopy once more with pig.Argyle silicon balloon-like conduit (12ch, 5 milliliters, lot number 027603) is used in experiment this time.Each conduit has the cylindrical compositions of one 15 millimeters long, and conduit top tip part diameter is identical with conduit, and Therapy lasted 7 days is used two pig (body weight is 20 and 21 kilograms), and the gentamicin concentration that draws is as follows:
Insert conduit microgram gentamycin/milliliter urine
After natural law pig 1 pig 2
1 2.9 1.25
2 4.7 0.25
3 4.6 0.95
4 3.4 0.27
5 5.3 0.59
6 / 1.25
7 / 3.40
When conduit when the 7th day takes out, compositions only discharges half, so gentamycin may be just blocked from the 5th day from the release on the device in pig 1 body.
The mucosal tissue of finding pig 1 trigonum in the 8th day obduction has signs of inflammation, and this sign may be because the top tip part of conduit causes in the bladder.Mucous membrane of urinary bladder of pig 2 and mucous membrane of urethra are all normal.
Claims (58)
1, a kind of preparation method for compositions, said composition by with the erosion rate sustained release active substance of the substantial constant on its one or more surfaces to aqueous phase, this method comprises mixes following composition: the mixture of the crystalline polymer that water-soluble basically crystalline polymer or some are water-soluble basically, surfactant or some surfactant mixtures, its consumption is 0.5% of crystalline polymer and a surfactant weight, this surfactant comprises and has at least one regional structure that adapts with crystalline polymer and be a kind of chemical compound or some chemical compounds of lipophilic another regional structure at least basically, this chemical compound has the fusing point that is lower than crystalline polymer, at least a active substance and random a kind of filler; Mix above-mentioned composition and form a kind of matrix, this matrix comprises surfactant or some surfactant mixtures of dispersed crystalline polymer phase, basically be scattered in the active substance that is arranged in the mutually univocal zone of crystalline polymer on crystalline polymer phase and/or the geometry and/or is scattered in surfactant equably, thus, this surfactant and/or active substance reduced in the crystalline polymer matrix and between the granule of crystalline polymer matrix itself and slit in the affinity of water.Therefore therefore, eliminated the infiltration of water on the interface between the polymer crystallization basically, be exposed on one or more surfaces of medium the water real Na cottonrose hibiscus an enclosure for storing grain cooked food of sculling by compositions and cherish the bucktooth enlightening of fainting suddenly and call on that matter plinth of tool that ticks to coughing
2, according to a kind of method of claim 1, wherein, crystalline polymer and surfactant are mixed, be heated to the temperature that is enough to melt polymer simultaneously and stir, so that obtain uniform basically mixture, active substance is joined in the polymer and surfactant mixtures of fusing, or before heating, join in this mixture, subsequently with the mixture forming and the cooling that make.
3, according to a kind of method of claim 1 or 2, wherein, by extrude, the method for coextrusion, injection moulding or compression forming and with composition molding.
4, according to a kind of method in aforementioned any claim, wherein, crystalline polymer comprises Polyethylene Glycol.
5, according to a kind of method in aforementioned any claim, wherein, crystalline polymer is homopolymer and/or copolymer.
6, according to a kind of method in aforementioned any claim, wherein, crystalline polymer comprises the block copolymer of Polyethylene Glycol and/or oxirane and propylene oxide.
7, according to a kind of method of claim 6, wherein, block copolymer comprises based on the weight of block up to about 30% propylene oxide, and have the above molecular weight of about 5000 dalton, typically be about 5000-30,000 dalton, more typically be about 800-15,000 dalton.
8, according to a kind of method in aforementioned any claim, wherein, the crystalline polymer matrix comprises molecular weight and is about 2000-500,000 daltonian Polyethylene Glycol, typically be about 5000-100,000 dalton more typically is about 10,000-50,000 dalton, especially typically be about 20,000-35,000 dalton.
9, according to a kind of method in aforementioned any claim, wherein, the fusing point of crystalline polymer matrix is about 20-120 ℃, and typically about 30-100 ℃, more about 40-80 ℃.
10, according to a kind of method of aforementioned any claim, wherein, the addition of active substance is approximately up to 60% of composition weight, typically approximately up to 50%.
11, according to a kind of method in aforementioned any claim, wherein, a kind of filler such as dextrin, Sucralfate, calcium hydroxy apetite, calcium phosphate or soap such as magnesium stearate join in crystalline polymer and the surfactant mixtures before heating or after the heating.
12, according to a kind of method in aforementioned any claim, wherein, the addition of filler and active substance is approximately up to 60% of composition weight, typically approximately up to 50%.
13, according to a kind of method in aforementioned any claim, wherein, active substance is medicine, vitamin or other nutritional supplement, antibacterial, the deodorizer of a kind of people of being used for or beast or other material that will be incorporated into aqueous environment continuously.
14, according to a kind of method in aforementioned any claim, wherein, active substance is the pharmaceutically active powder.
15, according to a kind of method of claim 14, wherein, the granular size of powder is about 0.1 micron~500 microns, typically is about 0.5~300 micron, more typically is about 1~200 micron, especially typically is about 5~100 microns.
16, according to a kind of method in aforementioned any claim, wherein, surfactant is the nonionic emulsifier that comprises one or more fatty acid esters and/or fatty acid ether.
17, according to a kind of method in aforementioned any claim, wherein, surfactant comprises and has 12~24 carbon atoms, is typically the fatty acid ester and/or the fatty acid ether of the carbochain of 12~20 carbon atoms.
18, according to a kind of method in aforementioned any claim, wherein, surfactant comprises palmitic acid or stearic ester and/or ether.
19, according to a kind of method in aforementioned any claim, wherein, surfactant comprises macrogol ester or ether, and polyethylene glycol ester or ether, poly-hydroxy ester or ether and/or sugar ester or ether are as dehydration Pyrusussuriensis (sugar) alcohol ester or ether.
20, according to a kind of method in aforementioned any claim, wherein, surfactant comprises polyethylene glycol mono stearate, particularly the PEG400 monostearate.
21, according to a kind of method in aforementioned any claim, wherein, the addition of surfactant is the about 0~60% of crystalline polymer and surfactant weight, for example: about 2-60%, 5-50%, typically about 10-40%, relatively typical more about 15~35,20-30% according to appointment according to appointment.
22, according to a kind of method in aforementioned any claim, wherein, compositions is formed as a kind of geometry, when matrix when aqueous phase is etched, this shape can make the surface area of substantial constant become and be exposed.
23, according to a kind of method of claim 22, wherein, compositions is garden post clavate and has the coating that is insoluble to substantially with liquid impermeable such as body fluid in the deenergized period of expection, this coating at one end or two ends opening is arranged.
24, according to a kind of method of claim 23, wherein, compositions molding by the coextrusion of coating and matrix and active substance, or adopt dip-coating subsequently or by the spraying or the solvent coating of dip-coating with extruding of injection moulding, compression forming or matrix and active substance.
25, according to a kind of method of claim 23 or 24, wherein, coating comprises matrix and the surfactant with one or more water-soluble basically crystalline polymers, this coating is lower than the matrix material that contains active substance basically in the erosive speed of aqueous phase, thus, the area of substantial constant that contains the matrix of active substance is exposed in the erosion process of compositions, and thus, coating corrodes with the erosion of the matrix that contains active substance basically.
26, according to a kind of method of claim 23 or 24, wherein, coating corrodes back decomposition or broken at matrix.
27, according to a kind of method of claim 22, wherein, compositions is formed as the hollow cylinder shape.
28, according to a kind of method of claim 22, wherein, compositions is formed as the hollow hemisphere shape.
29, according to a kind of method of claim 22, wherein, compositions is formed as tablet or slab-like.
30, according to a kind of method in aforementioned any claim, wherein, active substance is scattered in the crystalline polymer matrix basically equably.
31, according to a kind of method of aforementioned any claim, wherein, active substance has regional structure and another lipophilic basically regional structure that at least one and crystalline polymer adapt, active substance be evenly dispersed in basically crystalline polymer mutually in.
32, according to a kind of method of claim 31, wherein, surfactant joins in the matrix material with about 0~2% amount of matrix weight and goes.
33, according to a kind of method of claim 23, wherein, by injection or extrusion molding compositions is formed some staggered basically transverse layers, they are layers that comprise crystalline polymer matrix and surfactant, active ingredient is substantially uniformly dispersed in this matrix, with a layer that comprises active ingredient, this active ingredient is substantially uniformly dispersed in crystalline polymer and surfactant.
34, according to a kind of method of claim 33, wherein, staggered layer comprises two or more different active substances respectively.
35, a kind of preparation is as the method for the multiple-unit pharmaceutical formulation of the active substance of sustained release, and this method comprises the combination according to the multiple individual unit of the compositions of aforementioned any claim preparation of the form that adopts capsule or tablet.
36; a kind of method for compositions for preparing the sustained release active substance to aqueous phase; this method comprises room temperature-vulcanized rubber (RTV rubber) combined with super-absorbent polymer particles and at least a active substance and forms a kind of matrix; in this matrix; super-absorbent polymer particles distributes equably basically and is present in the near surface of compositions; and; active substance disperses and/or is positioned at this matrix to go up univocal zone how much basically equably; thus; aqueous phase liquid can be penetrated into limited speed in the matrix; cause the super-absorbent polymer particles swelling and near the partial fracture of the matrix swelling granule; thus according to the distribution of active substance in matrix, it is discharged with the method for special control.
37, according to a kind of method of claim 36, wherein, catalyst and random a kind of cross-linking agent are added in the matrix material.
38, according to a kind of method of claim 36 or 37, wherein, RTV elastomeric material, super-absorbent polymer and catalytic promoter and/or cross-linking agent at room temperature are mixed together simultaneously and stir, before stirring or among stirring, active substance is joined in this mixture, subsequently with mixture forming.
39, according to any one method of claim 36 to 38, wherein, by extrude, the method for coextrusion, injection moulding or compression forming is composition molding.
40, according to any one method of claim 36 to 39, wherein, RTV rubber comprises the RTV silicone elastomer based on one or two composition of polydimethylsiloxane.
41, according to any one method of claim 36 to 40, wherein, super-absorbent polymer particles can keep semi-solid state when absorbing water or other liquid, and can absorb himself weight at least about 10 times water, typically at least about 100 times water, typical especially about 200 times water.
42, according to any one method of claim 36 to 41, wherein, super-absorbent polymer particles can keep semi-solid state when absorb body fluids, and can absorb at least 5 times body fluid of himself weight, typically at least about 20 times, especially typically at least about 40 times.
43, according to any one method of claim 36 to 42, wherein, super-absorbent polymer comprises polyacrylic acid, modified polyacrylic acid, carboxymethyl cellulose, modified carboxy methyl cellulose and/or cross-linking polyethylene pyrrolidone.
44, according to any one method of claim 36 to 43, wherein, super-absorbent polymer adds with about 5~75% amount of matrix weight, typically about 10-50%, relatively typical about 20~25%.
45, according to any one method of claim 36 to 44, wherein, active substance with composition weight up to about 60% amount and add, typically up to about 50%.
46, according to any one method of claim 36 to 45, wherein, active substance is people or medicine for animals, the material of vitamin or other nutritional supplement, antibacterial, deodorizer or another kind successive administration in water environment.
47, according to any one method of claim 36 to 46, wherein, active substance is the medicinal active powder.
48, according to a kind of method of claim 47, wherein, powder particle is about 0.1~500 micron, typically is about 0.5~300 micron and more typically is about 1~200 micron, especially typically is about 5~100 microns.
49, according to any one method of claim 36-48, wherein, compositions is formed as a kind of geometry, when matrix when aqueous phase is etched, this shape can make the surface area of substantial constant be exposed.
50, according to a kind of method of claim 49, wherein, compositions is formed as the cylinder clavate and has and is insoluble to basically in the deenergized period of expection or the coating of liquid impermeable such as body fluid, this coating at one end or two ends opening is arranged.
51, according to a kind of method of claim 50, wherein, compositions is by the co-extrusion modling of coating and matrix and active substance, or adopts dip-coating subsequently or apply with the solution of spraying or dipping with extruding of injection moulding, compression forming or matrix and active substance.
52, according to a kind of method of claim 49, wherein, compositions is formed as the hollow cylinder shape.
53, according to a kind of method of claim 49, wherein, compositions is formed as hollow hemisphere shape.
54, according to a kind of method of claim 49, wherein, compositions is formed as tablet or slab-like.
55, according to any one method of claim 36 to 54, wherein, active substance becomes and is evenly dispersed in matrix basically and has suffered.
56, according to a kind of method of claim 50, wherein, by injection or extrusion molding compositions is formed some staggered basically transverse layers, they are layers that comprise matrix, active ingredient optionally is substantially uniformly dispersed in this matrix, with a layer that comprises active ingredient, this active ingredient is evenly distributed in the matrix material basically.
57, according to a kind of method of claim 56, wherein, staggered layer comprises two or more different active ingredients respectively.
58, a method for the multiple-unit pharmaceutical formulation of preparation sustained release active substance, this method comprise the combination according to the multiple individual unit of the compositions of any one method preparation in the claim 36 to 57 of the form that adopts capsule or tablet.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPCT/DK88/00049 | 1988-03-24 | ||
DK8800049 | 1988-03-24 | ||
DK6062/88 | 1988-10-31 | ||
DK606288A DK606288D0 (en) | 1988-03-24 | 1988-10-31 | PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1037835A true CN1037835A (en) | 1989-12-13 |
Family
ID=8147145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN89103575.3A Pending CN1037835A (en) | 1988-03-24 | 1989-03-23 | The compositions of sustained release |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPH0774163B2 (en) |
CN (1) | CN1037835A (en) |
DK (1) | DK606288D0 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110740759A (en) * | 2017-04-05 | 2020-01-31 | 吉莱斯公司 | Improved superabsorbent material and method of making same |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3720386B2 (en) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | Drug release controlled formulation |
ES2255103T3 (en) * | 1996-10-25 | 2006-06-16 | Shire Laboratories Inc. | OSMOTIC DOSE ADMINISTRATION SYSTEM IN SOLUBLE FORM. |
JP2000344669A (en) * | 1999-03-30 | 2000-12-12 | Nikken Chem Co Ltd | Therophylline injection |
TW200930343A (en) * | 2007-09-21 | 2009-07-16 | Organon Nv | Drug delivery system |
-
1988
- 1988-10-31 DK DK606288A patent/DK606288D0/en not_active Application Discontinuation
-
1989
- 1989-03-22 JP JP1504081A patent/JPH0774163B2/en not_active Expired - Lifetime
- 1989-03-23 CN CN89103575.3A patent/CN1037835A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110740759A (en) * | 2017-04-05 | 2020-01-31 | 吉莱斯公司 | Improved superabsorbent material and method of making same |
Also Published As
Publication number | Publication date |
---|---|
JPH0774163B2 (en) | 1995-08-09 |
JPH03503415A (en) | 1991-08-01 |
DK606288D0 (en) | 1988-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2927950B2 (en) | Controlled release composition | |
US5618560A (en) | Controlled release erodible composition | |
JP4989217B2 (en) | Matrix composition for controlled delivery of drug substance | |
US5543156A (en) | Bioerodible devices and compositions for diffusional release of agents | |
CN1160079C (en) | Bubbling enteric coated preparations | |
EP2276470B1 (en) | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation | |
CN1228692A (en) | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof | |
CN86106637A (en) | Pharmaceutical composition capable of liquid-gel phase transition | |
JPH09509184A (en) | Controlled release composition | |
US20020119197A1 (en) | Process and system for controlled-release drug delivery | |
CN1084079A (en) | Ophthalmic composition | |
JP4800570B2 (en) | Sustained release pharmaceutical composition | |
CN1788688A (en) | Device and method for lowly invasively transplanting biological material | |
CN1468090A (en) | Slow release pharmaceutical preparation and method of administering same | |
JP2011518164A (en) | Dexamethasone formulation in biodegradable materials | |
CN1541090A (en) | Prepn. of sustained release pharmaceutical compsn. | |
CN1416340A (en) | Compsns for delivery of contisol antagonist | |
JP2004535473A (en) | Sustained release pharmaceutical composition | |
JP2008539240A (en) | Sustained release formulation | |
JP2011517699A (en) | Sulindac formulation in biodegradable material | |
CN1589133A (en) | Radioopaque slow release pharmaceutical system | |
CN1316900A (en) | Long time drug-sustained release preparation | |
JP2011508791A (en) | Fluocinolone formulation in biodegradable polymer carrier | |
CN1037835A (en) | The compositions of sustained release | |
CN1522158A (en) | Treatment of parasitic disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |